Pasithea Therapeutics Corp. Common Stock (KTTA)
Pasithea Therapeutics Corp. is a biotechnology company focused on developing novel therapies for psychiatric and neurological disorders. The company specializes in psychedelic and psychoplastogenic compounds, aiming to create innovative treatments for conditions such as depression, anxiety, and related mental health issues. Pasithea combines scientific research with clinical development to advance its therapeutic pipeline.
Company News
The neurofibromatosis type 1 market is expected to grow significantly due to advances in treatment, increased diagnoses, and ongoing clinical trials. Unmet needs in adult populations and systemic disease management create opportunities for new entrants and differentiated strategies.
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 100 points on Monday. The Dow traded up 0.26% to 36,341.44 while the NASDAQ rose 0.12% to 14,421.98. The S&P 500 also rose, gaining, 0.30% to 4,618.11. Check This Out: This Analyst With 84% Accuracy Rate Sees More Than 7% Upside In Broadcom - Here Are 5...
Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week
Insider buying has these NASDAQ & NYSE penny stocks on the Robinhood watch list this week. The post 4 Cheap Robinhood Stocks To Buy According To Insiders In August 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.